Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Regeneron Pharmaceuticals, Inc. REGN

Healthcare  —  Biotechnology
788.04 (7.98) (1.00%) as of 25 Sep
Market cap
$81.3B
P/E
18.8×
S&P 500 Member Revenue Champion (3y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) EV/EBITDA

As of 25 September 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a EV/EBITDA of 17.3×. Over the past ten years it has ranged from 5.9× (June 2022) to 56.4× (June 2015); the current reading is higher than 54% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 18.3× 15.07%
FY2024 15.9× (20.14%)
FY2023 20.0× 39.15%
FY2022 14.3× 107.64%
FY2021 6.9× (49.94%)
FY2020 13.8× (13.29%)
FY2019 15.9× 11.73%
FY2018 14.2× (20.72%)
FY2017 18.0× (34.01%)
FY2016 27.2× (34.66%)

Quarterly

Period EV/EBITDA Change
Jun 2026 13.5× (24.52%)
Mar 2026 17.8× (2.78%)
Dec 2025 18.3× 45.10%
Sep 2025 12.6× 7.51%
42 more quarters

Against its own ten years

Low 5.9× High 56.4×
Ten-year median 16.8×
Current reading's percentile 54

EV/EBITDA against peers

Company EV/EBITDA
INSM Insmed, Inc. compare n/m
RVMD Revolution Medicines, Inc. compare n/m
MRNA Moderna, Inc. compare n/m
REGN Regeneron Pharmaceuticals, Inc. 17.3×
RPRX Royalty Pharma PLC compare 22.0×
VRTX Vertex Pharmaceuticals Incorporated compare 25.2×
ALNY Alnylam Pharmaceuticals, Inc. compare 30.3×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 34.1×
ARGX argenex SE compare 35.1×
Biotechnology industry median 0.7×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on REGN